Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Exclusion Criteria

• •1. Participants who are breast-feeding and/or who have a positive pregnancy test result prior to receiving sibeprenlimab.
• •2. Participant has coexisting chronic kidney disease, other than IgAN.
• •3. Participant has a serum IgG value \<600 mg/dL at screening.
• •4. Participant is currently receiving or has received within 24 weeks prior to the firstdose of sibeprenlimab, systemic corticosteroids or immunosuppression (note:
• •topical, ophthalmic, rectal, intra-articular, inhaled corticosteroids are allowed).
• •5. Participant has uncontrolled hypertension (defined as systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg).
• •6. Participants who would be likely to require prohibited concomitant therapy during the trial.